ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a Final Written Decision following inter partes review (IPR), finding all 10 challenged claims of Exact Sciences' U.S. Patent No. 11,970,746 (the '746 patent) unpatentable. This decision follows the PTAB's July 2025 Final Written. ...

Core Viewpoint - Biogen Inc. reported stronger-than-expected fourth-quarter 2025 results, leading to a more than 3% increase in shares, and provided an optimistic profit outlook for 2026 [1] Financial Performance - Adjusted earnings per share for Q4 2025 were $1.99, exceeding the analyst consensus of $1.61 [1] - Revenue for the quarter was $2.28 billion, surpassing expectations of $2.21 billion, although it represented a 7% decline year over year [1] Growth Products - Growth products showed positive momentum, with revenue increasing by 6% year over year in the quarter [2] - Global in-market sales of LEQEMBI reached approximately $134 million, marking a 54% year-over-year increase [2] - ZURZUVAE generated about $66 million in revenue, indicating strong demand growth [2] - SKYCLARYS expanded its global patient base by roughly 30% in 2025 [2] 2026 Outlook - For fiscal 2026, Biogen forecasts adjusted earnings per share in the range of $15.25 to $16.25, above the analyst consensus of $14.92 [3] - The company anticipates total revenue to decline by a mid-single-digit percentage compared to 2025, with expected declines in multiple sclerosis products, excluding VUMERITY, partially offset by growth in newer therapies [3]

Big Tech is getting hammered during their earnings season. Software and tech stocks are getting hit in general—and I'm buying into the software meltdown for the record—but specifically for our hyperscalers, it's beenNewsletter Author | Investment Advisor | Top 5% of Experts on TipRanks | Long Signal, Short Noise | The Macro Obsession newsletter is a weekly brief on current events and trends in finance, tech, and the real economy. I am a macro-oriented and data-driven investor who obsesses over connecting do ...

The Global X Silver Miners ETF (NYSEARCA:SIL) offers exposure to silver mining companies, but the fund's current dividend profile raises serious questions about income sustainability. ...

What is the biggest driver. Because that need to consolidate has been around. Is it just that the regulation is letting the banks do this now.>> Well, scale has never been more important. And to put things in context, the bank that just sold, it takes them, it would have taken them a decade and a half of spending to equal what JP Morgan's going to be spending just on technology this year. So, it's never been more competitive.But also, the regulatory environment, it suppressed the level of bank mergers. I th ...

BENSALEM, Pa., Feb. 6, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Ramaco Resources, Inc. ("Ramaco" or the "Company") (NASDAQ: METC). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN RAMACO RESOURCES, INC. (METC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE MARCH 31, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law O ...

Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-depth cash flow analyses of E&P firms, and live chat discussion of the sector.Sign up today for your two-week free trial and get a new lease on oil & gas! ...

Core Insights - Philip Morris International Inc. reported fourth-quarter results that met analyst expectations, with adjusted earnings per share of $1.70 and revenue of $10.4 billion, slightly above the expected $10.39 billion [1] Group 1: Financial Performance - The company achieved adjusted diluted EPS of $7.54 for the full year 2025, reflecting a year-over-year growth of 14.8%, or 14.2% on a currency-neutral basis [2] - Revenue from smoke-free products constituted 41.5% of total net revenues and nearly 43% of total gross profit, marking increases of 2.8 and 3.2 percentage points compared to full-year 2024 [3] Group 2: Business Growth and Strategy - Smoke-free shipment volumes increased by 8.5% in the quarter, while traditional cigarette volumes saw a decline of 2.2% [2] - Philip Morris guided for fiscal 2026 adjusted EPS in the range of $8.38 to $8.53, surpassing the analyst consensus of $8.33 [4] - The company set new growth targets for 2026–2028, aiming for organic net revenue growth of 6% to 8%, organic operating income growth of 8% to 10%, and adjusted diluted EPS growth of 9% to 11%, excluding currency effects [4]

Key Takeaways BigBear.ai bolsters its defense AI platform with $250M Ask Sage acquisition, adding secure generative AI. BBAI raised its 2025 revenue forecast to $125M-$140M and held $456.6M in cash to support growth efforts. BigBear.ai reported improving net income, but revenue fell sharply, and operating losses widened in Q3 2025.BigBear.ai Holdings, Inc. (BBAI) , a competitor to Palantir Technologies Inc. (PLTR) in the artificial intelligence (AI) defense space, has remained highly volatile throughout 202 ...

SAN JOSE, Calif.--(BUSINESS WIRE)--A10 Networks (NYSE: ATEN), a leading provider of secure application services and solutions, today announced it will host an Investor Day in San Francisco on Thursday, February 19, 2026, at the Fairmont San Francisco. The Company's executive leadership team will outline A10's long-term growth framework across Legacy Networking, Next-Generation Networking, and Security. The event will include a live webcast and replay and is intended to provide investors with a. ...